We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+2.74%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$747M
AUM Growth
-$68.4M
Cap. Flow
-$45M
Cap. Flow %
-6.03%
Top 10 Hldgs %
35.25%
Holding
111
New
12
Increased
44
Reduced
34
Closed
21

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$16.1M
2
PODD icon
Insulet
PODD
+$15.9M
3
ICLR icon
Icon
ICLR
+$11.6M
4
HUM icon
Humana
HUM
+$10.1M
5
BSX icon
Boston Scientific
BSX
+$9.23M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$17.4M
2
THC icon
Tenet Healthcare
THC
+$16.2M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$15.6M
4
COR icon
Cencora
COR
+$13.9M
5
OSCR icon
Oscar Health
OSCR
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.27%
2 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
51
DELISTED
Avadel Pharmaceuticals
AVDL
$5.32M 0.71%
378,289
-9,481
-2% -$155K
STRO icon
52
Sutro Biopharma
STRO
$353M
$5.25M 0.7%
179,274
+269
+0.2% +$10.6K
FOLD
53
DELISTED
Amicus Therapeutics
FOLD
$4.98M 0.67%
502,463
+275,740
+122% +$2.83M
REPL icon
54
Replimune Group
REPL
$1.28B
$4.72M 0.63%
+525,000
New +$3.66M
PHLT
55
DELISTED
Performant Healthcare Inc
PHLT
$4.71M 0.63%
1,623,199
-35,901
-2% -$103K
LIVN icon
56
LivaNova
LIVN
$4.45B
$4.67M 0.63%
85,159
-59,841
-41% -$3.41M
URGN icon
57
UroGen Pharma
URGN
$2.39B
$4.61M 0.62%
274,465
+90,281
+49% +$1.28M
VCYT icon
58
Veracyte
VCYT
$3.6B
$4.54M 0.61%
209,475
-44,617
-18% -$938K
MLTX icon
59
MoonLake Immunotherapeutics
MLTX
$1.47B
$4.45M 0.6%
101,224
+153
+0.2% +$6.48K
CDMO
60
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$4.43M 0.59%
621,091
+350,955
+130% +$2.68M
RARE icon
61
Ultragenyx Pharmaceutical
RARE
$2.65B
$4.11M 0.55%
+100,000
New +$4.27M
FTRE icon
62
Fortrea Holdings
FTRE
$1.74B
$3.57M 0.48%
152,769
-275,035
-64% -$8.54M
ARVN icon
63
Arvinas
ARVN
$581M
$3.33M 0.45%
125,161
+182
+0.1% +$5.8K
NUVL
64
DELISTED
Nuvalent
NUVL
$3.25M 0.44%
42,888
-4,920
-10% -$350K
TGTX icon
65
TG Therapeutics
TGTX
$7.58B
$3.21M 0.43%
180,320
+25,281
+16% +$403K
VTYX
66
DELISTED
Ventyx Biosciences
VTYX
$2.68M 0.36%
1,160,022
-48,077
-4% -$200K
MRUS
67
DELISTED
Merus
MRUS
$2.67M 0.36%
45,152
-34,971
-44% -$1.69M
TERN
68
DELISTED
Terns Pharmaceuticals
TERN
$2.66M 0.36%
+390,270
New +$2.36M
NAMS icon
69
NewAmsterdam Pharma
NAMS
$3.32B
$2.6M 0.35%
135,376
-64,935
-32% -$1.3M
ESPR
70
DELISTED
Esperion Therapeutics
ESPR
$2.54M 0.34%
1,144,646
+1,749
+0.2% +$4.11K
BCRX icon
71
BioCryst Pharmaceuticals
BCRX
$2.71B
$2.47M 0.33%
+400,448
New +$2.21M
DVAX
72
DELISTED
Dynavax Technologies
DVAX
$2.43M 0.33%
216,822
-49,688
-19% -$578K
QTRX icon
73
Quanterix
QTRX
$139M
$2.33M 0.31%
176,377
+265
+0.2% +$4.43K
SIBN icon
74
SI-BONE Inc
SIBN
$851M
$1.98M 0.27%
153,015
+234
+0.2% +$3.34K
ELAN icon
75
Elanco Animal Health
ELAN
$11.1B
$1.82M 0.24%
126,042
-75,139
-37% -$1.2M
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Parkman Healthcare Partners held 111 positions worth $747M, down 8.4% from $815M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners withdrew a net $45M in Q2 2024, closing 21 positions and reducing 34 holdings. Its most notable exit was Inspire Medical Systems, an estimated $17.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Agios Pharmaceuticals worth $19.2M.

  • Parkman Healthcare Partners's largest Q2 2024 buy was Agios Pharmaceuticals: 446,416 shares worth $19.2M.
  • Parkman Healthcare Partners added most to Insulet in Q2 2024, an estimated $15.9M increase.
  • Parkman Healthcare Partners's biggest Q2 2024 reduction was Tenet Healthcare, cutting an estimated $16.2M.
  • Parkman Healthcare Partners fully exited Inspire Medical Systems in Q2 2024, selling an estimated $17.4M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $747M portfolio in Q2 2024.
  • Parkman Healthcare Partners opened 12 new positions and closed 21 in Q2 2024.
  • Parkman Healthcare Partners's portfolio value fell 8.4% quarter-over-quarter to $747M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.